Recovering from acute kidney damage isn't just about growing kidney cells—it also requires kidney tissue to stiffen ...
Morning Overview on MSN
Scientists may finally know why kidney patients are dying from heart disease
For years, doctors have watched patients with failing kidneys die not from kidney failure itself but from sudden heart ...
CalciMedica has terminated a Phase II study on its lead asset, Auxora (zegocractin), in acute kidney injury (AKI) with ...
As soon as you are wounded—whether from grabbing a hot pan or contracting the flu—you begin a unique journey through variable symptoms toward either recovery or death. This journey is called your ...
A new study published in the Journal of American Medical Association showed that when renal protection is a primary therapeutic objective, starting treatment with an SGLT2 inhibitor (SGLT2i) ...
A 74-year-old man with chronic kidney disease (CKD) and type 2 diabetes presented to our nephrology clinic for follow-up of diabetic kidney disease with a serum creatinine of 180 (reference range 59 ...
AriBio and RESTARI Announce Exclusive License Agreement for a Novel Program in Polycystic Kidney Disease and Cystic Liver Diseases ...
SGLT2 inhibitors were linked to better kidney outcomes than GLP-1 receptor agonists in Type 2 diabetes. Learn more about the clinical impact.
CalciMedica shares fell after the company stopped its Phase 2 KOURAGE trial for Auxora due to safety concerns.
Investing.com -- CalciMedica Inc. (NASDAQ:CALC) stock plunged 80% Wednesday after the company announced it was discontinuing its Phase 2 KOURAGE clinical trial for acute kidney injury following safety ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results